The genetic constructs switch on only in cancer cells and force them to become  “factories”  that produce any signal protein of choice, encoded in the genetic sequence. The proteins are used for imaging (diagnostic) or for activating the immune system  against the cancer  (therapeutic).  Earli has demonstrated the accuracy of its platform in pre-clinical studies in lung cancer and is already working on liver cancer and therapeutic applications.

Earli can  save hundreds of thousands  of lives per year.  Millions of unclear cancer screening results turn into clear, actionable diagnoses.  Instead of sending patients home without a clear diagnosis, they get treated  immediately,  preventing deadly metastases.  E.g., 50% of lung cancer patients suffer from recurrence, reducing their 5-year survival rate from 60% to 8%.